[press release] Valneva, a leading pure play vaccines biotech company, announced that it has signed a new research license agreement with Merial and a commercial license agreement with an undisclosed European company to develop veterinary vaccines using Valneva’s EB66 ® vaccine cell line platform. Valneva is member of Atlanpole Biotherapies.
The young company aims at becoming a European leader in gene therapy for the treatment of rare genetic diseases in ophthalmology for which no treatment exists to date. The company has launched the development of a medicine intended to treat a form of retinitis pigmentosa. This is possible thanks to the confidence of private investors and of the Public Investment Bank (BPIfrance), which will ensure its operation until the end 2015. Member of Atlanpole Biotherapies, Horama is also supported by IHU Cesti (European Center for Transplantation and Immunotherapy Sciences).
After a few years in R & D in the world of biotechnology, Céline Breda turned towards vaccine development at Sanofi Pasteur. In 2005, she became involved in a new challenge by choosing to join Vivalis, a Nantes company which was under creation, to work on their technology platform for the production of new vaccines. A change of strategy within the company has led her to the management of BE Vaccines, the first European subsidiary of the Indian Biological E company: a new challenge indeed!
Two major scientific articles validate Effimune’s drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system. Effimune announced the publication in January and February 2015 of two separate studies in major scientific journals which both provide proof of concept for immune system regulation through a therapeutic molecule developed by the Nantes biotech company. Michel Goldman, internationally recognized expert in Therapeutic Immunology, is named Chairman of Scientific Advisory Board.
[Press release] PPF Group has acquired a significant minority stake in Cytune Pharma SAS, a French biotechnology company focused on researching and developing new therapies for immune modulation aimed at enhancing immune response of patients suffering from cancer and infectious diseases. Cytune’s platform based on modified IL-15 offers the possibility of combinations with other immunotherapeutic strategies, including checkpoint inhibitors.
New member: Amadéite, a company of the Olmix Group, values the properties of algae in the human diet
The Olmix group, based in Bréhan is a pioneer of marine algae exploitation. Its Amadéite SAS subsidiary was created in 2011 to manage all the R & D group activities and to develop its expertise (for the complete managment of the R & D group activities and the developement of its expertise) in the blue biotechnology towards the "human care" sector.